A case report identifies chronic thrombotic microangiopathy induced by long-term imatinib therapy, suggesting potential risks of extended use.
Key Points
To highlight the rare occurrence of chronic thrombotic microangiopathy induced by long-term imatinib therapy in a patient with chronic myeloid leukemia.
Case report of a patient with chronic myeloid leukemia on low-dose imatinib for 17 years
Assessment of endothelial dysfunction and thrombotic microangiopathy characteristics
Longitudinal monitoring of symptoms and therapeutic effects
Chronic thrombotic microangiopathy developed after 17 years of treatment
Significant endothelial dysfunction was observed
Emphasized potential cumulative injuries from extended imatinib exposure